关于CDK7抑制剂研究的全球趋势和主题:图书统计分析
Jiamin Liu1, Ling He1, Wenjing Jiang1
1Department of Gynecology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Frontiers in pharmacology
|October 10, 2024
概括
向循环素依赖性激酶7 (CDK7) 抑制剂是一种有前途的癌症治疗方法. 本文献分析揭示了研究趋势,强调美国和中国是主要贡献者,并专注于涉及CDK7-介导转录的抗瘤策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 循环素依赖性激酶7 (CDK7) 在癌症发病和进展中起着至关重要的作用.
- 向转录的调节者CDK7是癌症治疗的一个有前途的治疗策略.
- 在过去的二十年中,对CDK7抑制剂的研究显著增加.
研究的目的:
- 系统地审查和视觉呈现CDK7抑制剂的研究格局.
- 确定CDK7抑制剂领域的未来研究热点和潜在方向.
- 为科学可靠性提供CDK7抑制剂研究的全面观点.
主要方法:
- 使用CiteSpace和VOSviewer软件进行图书统计分析.
- 检查过去二十年的出版数据.
- 出版国家,作者,机构,科学类别,引用期刊和关键词的分析.
主要成果:
- 分析了来自41个国家的426个出版物,引用了15892个来源.
- 自2016年以来,观察到CDK7抑制剂的研究迅速扩展.
- 美国和中国在出版量方面处于领先地位,美国在国际合作方面也处于领先地位.
- 最近的研究重点是与CDK7-介导转录相关的抗瘤策略.
结论:
- 识别研究努力,不断发展的模式,以及CDK7抑制剂开发的预测进展.
- CDK7抑制剂的知识结构包括药理机制,治疗点和癌症治疗策略.
- 目前的研究旨在了解癌症的进展,确定信号通路,并开发有效的临床治疗方法.
更多相关视频
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
14.8K
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
16.5K
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
